Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 History  





3 References  














Fluorodopa






العربية
Français
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Fluorodopa
Clinical data
Trade namesFluorodopa F18
Other names6-fluoro-L-DOPA, FDOPA
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid

CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H10FNO4
Molar mass214.18 g·mol−1
3D model (JSmol)
  • C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N

  • InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1

  • Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracerinpositron emission tomography (PET).[1]

The most common side effects are injection site pain.[2]

Medical uses[edit]

Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).[2]

History[edit]

In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).[3][4]

The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.[3] The trial was conducted at one clinical site in the United States.[3]

References[edit]

  1. ^ Deng WP, Wong KA, Kirk KL (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry. 13 (11): 1135–1140. doi:10.1016/S0957-4166(02)00321-X.
  • ^ a b "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.
  • ^ a b c "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  • ^ "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Fluorodopa&oldid=1214633391"

    Categories: 
    Catecholamines
    Radiopharmaceuticals
    Extrapyramidal and movement disorders
    Hidden categories: 
    Source attribution
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from April 2020
    Chem-molar-mass both hardcoded and calculated
    Articles containing unverified chemical infoboxes
     



    This page was last edited on 20 March 2024, at 04:43 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki